News | November 14, 2022
Biocon Biologics features on ASIA IP ELITE List 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Gansons is based in Thane (Maharashtra, India) with global representation in UK, USA, UAE, Central Asia, South Asia and South-East Asia.
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Subscribe To Our Newsletter & Stay Updated
